Kuvalanka Bolts Blueprint Medicines For COO Gig at Syros
Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
Sponsored · Whitepaper
What to Include in Your Life Sciences Company Fundraising Pitch Deck
What the most successful life sciences fundraising pitch decks all have in common
Brex
Sponsored · Whitepaper
Time Savings That Speed up Science
Monitor spending and save meaningful dollars with life sciences-specific rewards
Brex
Xconomy Insight · Webinar
Digital Healthcare Revolution Webinar Series
AI, drug discovery and development, IBM Watson Health, oncology, genomics & more